Core Insights - INmune Bio Inc. has transitioned from a mid-stage clinical company to a late-stage, registration-directed organization, focusing on harnessing the innate immune system to treat inflammatory diseases [4] - The company is preparing for significant regulatory submissions in 2026 and 2027, with two late-stage assets, CORDStrom™ and XPro™, expected to drive value for patients and shareholders [4] Financial Results - For the year ended December 31, 2025, the net loss attributable to common stockholders was approximately $45.9 million, compared to $42.1 million in 2024 [12] - Research and development expenses were approximately $20.7 million in 2025, down from $33.2 million in 2024, while general and administrative expenses increased to approximately $10.3 million from $9.5 million [12] - The company reported cash and cash equivalents of approximately $24.8 million as of December 31, 2025, an increase from $20.9 million in 2024 [17] CORDStrom™ Platform - CORDStrom™ is on track to file a Marketing Authorization Application (MAA) in the UK by mid-summer 2026, followed by anticipated submissions to the EMA and FDA [5] - The platform is designed to treat recessive dystrophic epidermolysis bullosa (RDEB) and has shown systemic disease-modifying capabilities in clinical trials [5][6] XPro™ Platform - XPro™ is advancing towards an adaptive Phase 2b/3 registrational pathway for early Alzheimer's Disease, with alignment achieved with the FDA [5] - The platform has reported zero cases of ARIA (Amyloid-related imaging abnormalities) across all clinical studies, distinguishing it from other therapies [8] Upcoming Events and Milestones - The company has scheduled a face-to-face meeting with the UK's MHRA in mid-May 2026 as part of its regulatory strategy [11] - INmune Bio's MINDFuL trial data was featured at the AD/PD 2026 conference, highlighting the importance of patient selection in clinical trials [5] Operational Readiness - The company has completed three commercial pilot-scale manufacturing runs at its Stevenage facility, ensuring readiness to supply the market upon regulatory approval [11] - INmune Bio estimates that its current cash position provides a runway through Q1 2027, supporting ongoing operations and clinical development [5]

Core Insights - Pfizer (PFE) and AstraZeneca (AZN) are leading players in the oncology sector, with significant revenue contributions from this area [1][2] - Pfizer's oncology sales account for over 25% of total revenues, growing by 9% in H1 2025, while AstraZeneca's oncology sales represent around 43% of total revenues, increasing by 16% in the same period [1][2][11] - Both companies have robust R&D pipelines that are expected to drive future growth [3] Pfizer Overview - Pfizer's acquisition of Seagen in 2023 has bolstered its oncology position [4] - Non-COVID operational revenues are improving, with key products generating $4.7 billion in H1 2025, a 15% operational increase year-over-year [5] - Pfizer anticipates $7.7 billion in cost savings by the end of 2027 and projects a revenue CAGR of approximately 6% from 2025 to 2030 [6] - Challenges include potential declines in COVID-related sales and significant patent expirations expected between 2026 and 2030, impacting key products [7][8] AstraZeneca Overview - AstraZeneca's portfolio includes several blockbuster drugs, with sales exceeding $1 billion, contributing to strong revenue growth [9] - The company plans to launch 20 new medicines by 2030, targeting $80 billion in total revenues [12] - AstraZeneca's newer drugs are contributing positively to top-line growth in 2025 [10] - Challenges include the impact of Medicare Part D redesign on key drug sales and competition from generics and biosimilars [13][14] Financial Estimates and Performance - Pfizer's 2025 sales and EPS estimates indicate modest growth of 0.3% and 1.0%, respectively, with EPS estimates rising from $3.05 to $3.14 [15] - AstraZeneca's 2025 sales and EPS estimates suggest stronger growth of 8.4% and 11.4%, with EPS estimates increasing from $4.50 to $4.58 [16] - Year-to-date stock performance shows Pfizer declining by 9.0%, while AstraZeneca has increased by 17.6% [18] Valuation and Dividend Yield - AstraZeneca's shares trade at a forward P/E ratio of 15.44, while Pfizer's are at 7.79, indicating a more attractive valuation for Pfizer [19] - Pfizer offers a higher dividend yield of 7.1% compared to AstraZeneca's 2.4% [22] - AstraZeneca has a higher return on equity at 32.8% versus Pfizer's 21.4% [22] Investment Outlook - Both companies are rated with a Zacks Rank 3 (Hold), making it challenging to determine a clear investment preference [23] - AstraZeneca is viewed as a safer investment due to its efficient profitability and clearer growth targets, despite Pfizer's attractive valuation and dividend yield [25]